RS59912B1 - Metode za tretiranje ili prevenciju migrenske glavobolje - Google Patents

Metode za tretiranje ili prevenciju migrenske glavobolje

Info

Publication number
RS59912B1
RS59912B1 RS20200165A RSP20200165A RS59912B1 RS 59912 B1 RS59912 B1 RS 59912B1 RS 20200165 A RS20200165 A RS 20200165A RS P20200165 A RSP20200165 A RS P20200165A RS 59912 B1 RS59912 B1 RS 59912B1
Authority
RS
Serbia
Prior art keywords
treating
methods
migraine headache
preventing migraine
preventing
Prior art date
Application number
RS20200165A
Other languages
English (en)
Inventor
Hong Sun
Eduardo Dunayevich
Robert A Lenz
Gabriel Vargas
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of RS59912B1 publication Critical patent/RS59912B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)
RS20200165A 2015-04-24 2015-08-10 Metode za tretiranje ili prevenciju migrenske glavobolje RS59912B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562152708P 2015-04-24 2015-04-24
EP15754071.7A EP3285803B1 (en) 2015-04-24 2015-08-10 Methods for treating or preventing migraine headache
PCT/US2015/044479 WO2016171742A1 (en) 2015-04-24 2015-08-10 Methods for treating or preventing migraine headache

Publications (1)

Publication Number Publication Date
RS59912B1 true RS59912B1 (sr) 2020-03-31

Family

ID=53969433

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200165A RS59912B1 (sr) 2015-04-24 2015-08-10 Metode za tretiranje ili prevenciju migrenske glavobolje

Country Status (30)

Country Link
US (3) US10259877B2 (sr)
EP (2) EP3653225A1 (sr)
JP (4) JP6392471B2 (sr)
KR (1) KR102464415B1 (sr)
CN (2) CN108156814B (sr)
AU (2) AU2015392215B2 (sr)
BR (1) BR112017022772A2 (sr)
CA (1) CA2984254C (sr)
CL (1) CL2017002686A1 (sr)
CY (1) CY1123211T1 (sr)
DK (1) DK3285803T3 (sr)
ES (1) ES2771925T3 (sr)
HK (1) HK1250914A1 (sr)
HR (1) HRP20200056T1 (sr)
HU (1) HUE048528T2 (sr)
IL (2) IL255114B (sr)
JO (2) JOP20200116A1 (sr)
LT (1) LT3285803T (sr)
MA (2) MA51815A (sr)
MX (2) MX2017013627A (sr)
PH (1) PH12017501934A1 (sr)
PL (1) PL3285803T3 (sr)
PT (1) PT3285803T (sr)
RS (1) RS59912B1 (sr)
RU (1) RU2707745C2 (sr)
SG (2) SG11201708607WA (sr)
SI (1) SI3285803T1 (sr)
TW (2) TWI728953B (sr)
WO (1) WO2016171742A1 (sr)
ZA (1) ZA201707179B (sr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
CA2943551A1 (en) 2014-03-21 2015-09-24 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
RU2770066C2 (ru) 2017-03-02 2022-04-14 Бет Изрейэл Диконисс Медикал Сентер, Инк. Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
US20200207844A1 (en) * 2017-09-12 2020-07-02 Igc Bio, Inc. Anti-vegf antibody
US10738110B2 (en) 2018-01-12 2020-08-11 Amgen Inc. PAC1 antibodies and uses thereof
SG11202009629YA (en) * 2018-04-02 2020-10-29 Amgen Inc Erenumab compositions and uses thereof
EP4302828A3 (en) * 2018-07-05 2024-01-17 Allergan Pharmaceuticals International Limited Combination therapy with cgrp antagonists and clostridial derivatives
JP2022516956A (ja) 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療
MA55815A (fr) * 2019-05-02 2022-03-09 H Lundbeck As Traitement de céphalées à l'aide d'anticorps anti-cgrp
US20210121541A1 (en) 2019-07-05 2021-04-29 Allergan Pharmaceuticals International Limited CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
WO2021005493A1 (en) 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and botulinum toxins for the treatment of inflammatory and neurologic disorders
WO2021005497A1 (en) 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders
AU2020405091A1 (en) * 2019-12-18 2022-07-14 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
EP4301362A1 (en) 2021-03-02 2024-01-10 CGRP Diagnostics GmbH Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0590076A4 (en) 1991-06-14 1997-02-12 Dnx Corp Production of human hemoglobin in transgenic pigs
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
AU673347B2 (en) 1992-03-17 1996-11-07 Novartis Ag Genetically engineered antibodies
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
JPH10504457A (ja) 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド カルシトニンレセプター
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
AU6596096A (en) 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
WO2003027252A2 (en) 2001-09-27 2003-04-03 Merck & Co., Inc. Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
EA008744B1 (ru) 2002-08-12 2007-08-31 Актавис Груп Хф. Применение соединений антагонистов кальцитонин генсвязанного пептида (cgrp) для лечения псориаза
US20040176577A1 (en) 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
CA2849552A1 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
RS52036B (sr) 2004-12-21 2012-04-30 Medimmune Limited Antitela usmerena na angiopoetin-2 i njegove upotrebe
DE102004063753A1 (de) 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
WO2006134692A1 (ja) 2005-06-16 2006-12-21 Univ Shinshu アドレノメデュリンを有効成分として含む血管新生剤
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
ME00419B (me) * 2005-11-14 2011-10-10 Rinat Neuroscience Corp Antigonistička antitijela usmjerena protiv kalcitonita, peptida povezanog sa genom i postupkom njihovog korišćenja
CA2629415A1 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam tricyclic cgrp receptor antagonists
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
WO2007133491A1 (en) 2006-05-09 2007-11-22 Merck & Co., Inc. Substituted spirocyclic cgrp receptor antagonists
BRPI0715141A2 (pt) 2006-08-03 2013-06-04 Astrazeneca Ab agente de ligaÇço alvejante, anticorpo isolado, fragmento de anticorpo isolado, molÉcula de Ácido nucleico, vetor, cÉlula hospedeira, mÉtodos para produzir um agente de ligaÇço alvejado, para produzir um anticorpo, para produzir um fragmento de anticorpo, para tratar um tumor maligno em um animal, para tratar inflamaÇço, e para inibir a interaÇço de alfabeta6 com seu ligando, e, conjugado
CA2683581A1 (en) 2007-04-11 2008-10-23 Merck & Co., Inc. Cgrp receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
WO2008130524A1 (en) 2007-04-16 2008-10-30 Merck & Co., Inc. Aryl heterocyclic cgrp receptor antagonists
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
MX2010009724A (es) 2008-03-04 2010-09-28 Pfizer Ltd Procedimientos de tratamiento del dolor inflamatorio-.
AU2009257733A1 (en) 2008-06-12 2009-12-17 Merck Sharp & Dohme Corp. Branched 3- and 6-substituted quinolines as CGRP receptor antagonists
FR2934597B1 (fr) 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
JP2012502995A (ja) 2008-09-18 2012-02-02 メルク・シャープ・エンド・ドーム・コーポレイション 二環式ジヒドロイミダゾロンｃｇｒｐ受容体アンタゴニスト
EP2340025B1 (en) 2008-10-03 2014-10-15 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
JO3330B1 (ar) 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
JOP20190250A1 (ar) * 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
DK2709662T3 (da) * 2011-05-20 2019-11-04 Alderbio Holdings Llc Anvendelse af anti-cgrp- eller anti-cgrp-r-antistoffer eller antistoffragmenter til behandling eller forebyggelse af kroniske og akutte former for diarré
ES2893073T3 (es) 2011-05-20 2022-02-07 H Lundbeck As Composiciones anti CGRP y uso de las mismas
CN107827982B (zh) * 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
JP6283408B2 (ja) 2013-03-15 2018-02-21 アムジェン インコーポレイテッド ヒトｐａｃ１抗体
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CA2943551A1 (en) 2014-03-21 2015-09-24 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
UY36302A (es) * 2014-09-15 2016-04-29 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas

Also Published As

Publication number Publication date
CA2984254A1 (en) 2016-10-27
TWI799849B (zh) 2023-04-21
US20190256607A1 (en) 2019-08-22
AU2015392215B2 (en) 2022-04-07
MA41932B1 (fr) 2020-04-30
AU2015392215A1 (en) 2017-11-09
TW202130369A (zh) 2021-08-16
HRP20200056T1 (hr) 2020-04-03
US20160311913A1 (en) 2016-10-27
IL255114A0 (en) 2017-12-31
LT3285803T (lt) 2020-02-10
RU2017140789A3 (sr) 2019-05-24
CN113908268A (zh) 2022-01-11
SG10202004282RA (en) 2020-06-29
JOP20200116A1 (ar) 2017-06-16
JO3559B1 (ar) 2020-07-05
EP3285803A1 (en) 2018-02-28
IL291153B2 (en) 2023-06-01
MX2017013627A (es) 2018-07-06
JP2020143115A (ja) 2020-09-10
DK3285803T3 (da) 2020-02-17
MX2021013327A (es) 2021-11-17
US11466090B2 (en) 2022-10-11
KR20180002711A (ko) 2018-01-08
WO2016171742A1 (en) 2016-10-27
PH12017501934A1 (en) 2018-03-19
SI3285803T1 (sl) 2020-02-28
RU2707745C2 (ru) 2019-11-29
JP6707590B2 (ja) 2020-06-10
MA51815A (fr) 2020-12-23
PT3285803T (pt) 2020-02-18
CN108156814B (zh) 2021-07-09
JP2019001800A (ja) 2019-01-10
TW201637667A (zh) 2016-11-01
PL3285803T3 (pl) 2020-06-01
US20230020514A1 (en) 2023-01-19
HUE048528T2 (hu) 2020-07-28
RU2017140789A (ru) 2019-05-24
US10259877B2 (en) 2019-04-16
EP3653225A1 (en) 2020-05-20
EP3285803B1 (en) 2019-12-18
JP2022126724A (ja) 2022-08-30
IL255114B (en) 2022-04-01
KR102464415B1 (ko) 2022-11-04
JP6392471B2 (ja) 2018-09-19
SG11201708607WA (en) 2017-11-29
ES2771925T3 (es) 2020-07-07
BR112017022772A2 (pt) 2018-07-31
ZA201707179B (en) 2020-01-29
HK1250914A1 (zh) 2019-01-18
CL2017002686A1 (es) 2018-05-11
JP2018513871A (ja) 2018-05-31
CN108156814A (zh) 2018-06-12
TWI728953B (zh) 2021-06-01
IL291153A (en) 2022-05-01
CY1123211T1 (el) 2021-12-31
AU2022204866A1 (en) 2022-08-18
CA2984254C (en) 2019-09-24

Similar Documents

Publication Publication Date Title
IL291153A (en) Methods for treating or preventing migraine headaches
IL265343A (en) Treatment of persistent migraine
HK1251614A1 (zh) 用於惡性腫瘤的治療的方法
IL254760A (en) A method for treating cancer
IL304252A (en) Cancer treatment methods
IL289947A (en) A method for treating cancer
IL265335A (en) Treating cluster headache
EP3171878A4 (en) Methods for treating paramyxoviruses
HK1244217A1 (zh) 用於治療蛋白質病的方法
HK1248135A1 (zh) 用於治療癌症的聯合方法
PL2913284T3 (pl) Sposób oraz urządzenie do obróbki części
IL271211A (en) Migraine treatment
ZA201607068B (en) Methods for treating hypersomnia
PT3250218T (pt) Péptido natkide para o tratamento da obesidade
IL249616A0 (en) Methods for treating inflammation